Comparative Pharmacology
Head-to-head clinical analysis: AMJEVITA versus SIMPONI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMJEVITA versus SIMPONI.
AMJEVITA vs SIMPONI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.
Golimumab is a human monoclonal antibody that binds to and neutralizes tumor necrosis factor alpha (TNF-α), inhibiting its interaction with TNF receptors and thereby reducing inflammatory responses.
Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.
Simponi (golimumab) is administered subcutaneously. For adult rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: 50 mg once monthly. For ulcerative colitis: 200 mg subcutaneously at week 0, then 100 mg at week 2, then 100 mg every 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 10-20 days) in patients receiving 40 mg every other week. This long half-life supports biweekly dosing.
Terminal elimination half-life approximately 12-14 days (mean 12.3 days in rheumatoid arthritis patients). Supports subcutaneous dosing every 2 weeks.
Adalimumab (AMJEVITA) is eliminated primarily via intracellular catabolism, with negligible renal or biliary excretion. No intact drug is excreted in urine. The Fe receptor-mediated recycling contributes to long half-life.
Primarily degraded into small peptides and amino acids via reticuloendothelial system; no significant renal or biliary elimination. Less than 0.1% excreted unchanged in urine.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor